From Rescue to Interception: The PREVENT 2-LATE Framework for Advanced Heart Failure.

The management of advanced heart failure has been transformed by two parallel developments that have not yet been fully translated into clinical practice. Heart transplantation and durable left ventricular assist device (LVAD) support confer contemporary 1-year survival approaching 90%; yet these therapies are frequently deployed only after the onset of progressive right ventricular dysfunction, cardiorenal injury, severe frailty, and hemodynamic instability which are conditions that elevate procedural risk, impair long-term outcomes, and may ultimately preclude candidacy for advanced therapies altogether. The central limitation in advanced heart failure is therefore no longer the absence of effective therapies, but the failure to identify and refer patients during the therapeutic window when physiologic reserve remains intact. This paper advances two related but distinct objectives. First, we propose PREVENT 2-LATE (PReserve Eligibility Via Early, Necessary Transfer), a pragmatic referral framework in which the presence of any two of four early signals including escalating Loop diuretic requirements, recurrent Admissions, Therapy intolerance, and Early electrical, echocardiographic or end-organ deterioration supplemented by persistently elevated natriuretic peptides - should prompt consideration for referral through shared care to an advanced heart failure program. These LATE criteria are designed to identify patients earlier in the disease trajectory than existing frameworks, while the full breadth of advanced therapy options are still intact. We further propose a multidisciplinary in-reach model, embedding advanced heart failure expertise within high-risk cardiovascular programs including electrophysiology, structural heart, cardiogenic shock, cardiac surgery, and specialized cardiomyopathy services, to proactively identify and intercept residual risk before conventional referral triggers emerge. Second, and equally important, this paper provides a consolidated framework for contemporary LVAD best practices, an area in which clinical evidence has advanced rapidly but awareness and adoption remain inconsistent. We synthesize current evidence on morbidity decompression, pharmacologic optimization including RAAS inhibition, myocardial recovery, frailty reversibility, and therapeutic sequencing including LVAD-first strategies, with the explicit goal of equipping clinicians to deploy these therapies earlier and more confidently. Critically, PREVENT 2-LATE is not designed to increase utilization of any single modality. Both heart transplantation and LVAD support are effective, and the framework exists precisely to preserve optionality across the full spectrum of advanced heart failure therapies, enabling expert multidisciplinary teams to match the right intervention to the right patient at the right time. The future of advanced heart failure lies not in increasingly urgent rescue after irreversible decline, but in systematic interception while options remain.